TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05357066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of the placebo (oxygen-air mixture \[FiO2 ≈0.3\]), will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
Study: NCT05429866
Drug: Checkpoint Blockade, Immune
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint blockade drugs target the immune system by blocking control pathways regulating anti-tumor immunity and thereby reinvigorate their activities against cancer.
Study: NCT05390814
Drug: PET-MRI
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]-Fludarabine imaging in the diagnostic workup of primary central nervous system lymphomas: a PET-MRI pilot study
Study: NCT05980572
Drug: Nonsteroidal anti-inflammatory drugs (aceclofenac)
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will be prescribed two weeks of nonsteroidal anti-inflammatory drugs (aceclofenac) .
Study: NCT05168683
Drug: Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing with light meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing or radiolabelled ALLN-346 fast or slow release tablets or capsules. Scintigraphic images will be taken
Study: NCT05168683
Drug: Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing in fasted/fed state
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selected dosing of Part One treatments in fasted and/or fed states
Study: NCT06447194
Drug: Ropivacaine, Epinephrine, Clonidine, and Ketorolac Injection Cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Please refer to description for interventional group.
Study: NCT06229548
Drug: SYH2053
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT06229548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT05890534
Drug: Pycnogenol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.
Study: NCT05890534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.
Study: NCT05914688
Drug: LY3209590 (Formulation 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05914688
Drug: LY3209590 (Formulation 2)
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT04521387
Drug: Corticosteroid Injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection in the painful area of humeral epicondyle.
Study: NCT05459844
Drug: Lutetium[177Lu] Oxodotreotide Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four administrations of 7.4 GBq (200 mCi) Lutetium\[177Lu\] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.
Study: NCT06509503
Drug: Vaginal Ring
Normalized name: NuvaRing Vaginal Ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: The arm will include 200 migraine patients diagnosed according to ICHD3-beta criteria. The patients are users of mechanical contraceptive methods and will receive propranolol 80-160mg daily and ibuprofen 200-400 mg only in acute migraine attacks for 3 months.
Study: NCT05567770
Drug: Androgen Deprivation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 2 patient with Polymetastatic disease will receive Actinium-J591 and Androgen Deprivation therapy (ADT)
Study: NCT06158919
Drug: Fruquintinib、Nivolumab、Sintilimab、Oxaliplatin、Teysuno、Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment period: A total of 6 cycles of combined treatment Fruquintinib: 4 mg/d, qd po, d1-14, q3w. Nivolumab: 360mg iv.gtt d1, q3w or Sintilimab: 200mg iv.gtt d1, q3w SOX : Oxaliplatin 130mg/m2 iv.gtt d1, Teysuno 40mg/m2 p.o.b.i.d. d1\~ 14q3w. Or XELOX regimen: oxaliplatin 130mg/m2 iv.gtt d1 Capecitabine 1000mg/m2 p.o. b.i.d. d1\~ 14q3w.~Maintenance treatment period:~Fruquintinib: 4 mg/d, qd po, d1-14, q3w. Nivolumab: 360mg iv.gtt d1, q3w or Sintilimab: 200mg iv.gtt d1, q3w Teysuno 40mg/m2 p.o.b.i.d. d1\~14 q3w or Capecitabine 1000mg/m2 p.o.b.i.d. d1\~14 q3w.~Maintenance of treatment until disease progression or toxicity becomes intolerable.
Study: NCT06124937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The comparator group will receive a matching placebo from 3 days before surgery until discharge from the hospital.
Study: NCT06551181
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of placebo is administered intramuscularly at Day 1.
Study: NCT05135130
Drug: ON101 Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable in this retrospective study
Study: NCT05019040
Drug: PA1010
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF as control
Study: NCT05942625
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of matching dose ofplacebo
Study: NCT04792424
Drug: Vasopressor
Normalized name: Vasopressor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine
Study: NCT04852406
Drug: Protocol-based management of perioperative antithrombotic therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative antithrombotic therapy is managed according to the latest expert consensus published in the Chinese Medical Journal, 2020.
Study: NCT04852406
Drug: Routine management of perioperative antithrombotic therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative antithrombotic therapy is managed according to current routine practice.
Study: NCT06724432
Drug: oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin treated children receive a single dose of oral melatonin 0.5 mg/kg (for a max 10 mg) in a fixed volume of 5 mL of water , 1 hour before induction of anesthesia for surgery
Study: NCT06724432
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children in the Control group receive 5 ml of 5% dextrose solution once 1 hour before induction of anesthesia
Study: NCT05785390
Drug: NP-101
Normalized name: NP Thyroid Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP-101 is an organically derived, GMP manufactured product covered under IND #152687.
Study: NCT04642404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug will be a solution with the same taste, texture and color as the drug.
Study: NCT06323148
Drug: No adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant therapy
Study: NCT04767191
Drug: artemether lumefantrine
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drugs are approved and in use by the Kenya Ministry of Health as the 1st and 2nd line treatment for malaria. The study is to assess the continued efficacy of the two drugs in the treatment of uncomplicated malaria.
Study: NCT04516993
Drug: The best treatment selected by local doctors(Aspirin, Recombinant Tissue Plasminogen Activator, Urokinase, Thrombectomy)
Normalized name: Doctor's Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best treatment arm
Study: NCT04751071
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet once daily for 6 weeks plus the standard therapy
Study: NCT05516979
Drug: 100 mg AP1189
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP1189 tablets for oral use
Study: NCT05516979
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for oral use
Study: NCT05076019
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
Study: NCT05055583
Drug: Adjuvant treatment stage
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperatively, a comprehensive evaluation will be conducted by the investigator, and the intention will receive maintenance therapy within 6-12 weeks of the MDT assessment. Toripalimab: a fixed dose of 80 mg (2ml)/vial, IV, D1, a full dose of 240 mg at one time, every 3 weeks administered until PD or intolerable toxicity, for a maximum duration of 1 year.
Study: NCT05980689
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During neo-CRT: 825mg/m2 bid Monday-Friday per week
Study: NCT05603403
Drug: Probiatop
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 sachet orally, 2 times a day, for 42 days
Study: NCT05630404
Drug: Surgical ESPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: In group IE, transverse processes will be palpated before sewing the surgical incision by the surgery team. The local anesthetic solution will be administered after the needle contacts the transverse process and its location is confirmed by negative aspiration. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 5 mL of solution will be injected the proper injection site. Local anesthetic solution will be injected at 4 levels along the surgical incision line. A dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL).~Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia.
Study: NCT05630404
Drug: US guided ESPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: US guided ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle 2 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block in each side (total 40 mL).~Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia.
Study: NCT03637387
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT00277693
Drug: Spironolactone (drug)
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05594680
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) is the first-line therapy for treatment of RA patients. MTX suppresses proliferation of synovial fibroblasts, modulates cytokine synthesis and superoxide anion production, and inhibits neutrophil chemotaxis.
Study: NCT05594680
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06199440
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: First group are chronic periodontitis patients with diabetes mellitus type II who received scaling and root planning.
Study: NCT06199440
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second group will receive 250 mg of azithromycin per day for a period of 5 days, after an initial dose of 500 mg one hour before NSPT.
Study: NCT06199440
Drug: Group III
Normalized name: Corticosteroids, potent (group III)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third group are Type 2 DM patients who received doxycycline 20mg twice/day.~Gingival crevicular fluid will be collected at 0, 1, and 3 months to assess Serum Resistin using a human Resistin enzyme-linked immunosorbent assay Kit following the manufacturer's protocol.
Study: NCT05478044
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid IV ampoules (20%).
Study: NCT06409078
Drug: Western medicine group
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with irritable bowel syndrome were given pivotal ammonium bromide tablets orally at 50 mg three times daily for seven days in the Western medicine group.
Study: NCT04807400
Drug: Background lipid lowering therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: lipid-lowering therapy (such as a statin and/or ezetimibe) as background therapy
Study: NCT06633185
Drug: phenytoin cream
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: application of the cream after internal anal sphincterotomy versus non application.
Study: NCT06633185
Drug: no phenytoin cream
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non application of the phenytoin cream
Study: NCT04875975
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Pharmaceutical form: Solution for infusion~* Route of administration: Subcutaneous use~Subjects will receive placebo in a pre-specified sequence during the Treatment Period.
Study: NCT04937816
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05876767
Drug: SAR444336
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or repeated dose subcutaneous injection
Study: NCT05876767
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or repeated dose subcutaneous injection
Study: NCT06701331
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets taken orally once a day (Or equivalent oral solution taken two times a day)
Study: NCT05212389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05734612
Drug: Placebo (lactose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the control group receive loading dose of placebo (lactose) 1 x 2 mg followed by lactose 2 x 0,5 mg daily for two consecutive days.
Study: NCT05545384
Drug: Immediate Azathioprine (1st attack)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients randomized in Immediate Azathioprine group will benefit from immediate treatment with azathioprine. Treatment will be started at 2mg/kg or at 1mg/kg if the patient has a partial activity which would be increased slowly according the 6-TGN activity and clinical and biological tolerance at Week 2 for patient with partial activity or M1 for patient without TPMT activity deficit.~Only for patient with partial deficit and whose 6-TGN activity is low, azathioprine would be increased at 3mg/kg/d at Week 6 and without exceeding a total daily dose of 150 mg.
Study: NCT05545384
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will be treated according to standard care
Study: NCT06058039
Drug: NMRA-335140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
Study: NCT06058039
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally
Study: NCT05813171
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take the placebo capsules in addition to standard treatment for a year.
Study: NCT06093230
Drug: Deuremidevir Hydrobromide Tablets
Normalized name: hydrobromic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: JT001 single dose, 0.3g
Study: NCT06123455
Drug: XELOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin + capecitabine
Study: NCT06123455
Drug: SOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin + S-1 (tegafur/gimeracil/oteracil potassium)
Study: NCT06142318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose climbing started two weeks before the start of radiotherapy, and the maintenance dose of 600mg bid was reached in the third week until the end of radiotherapy.
Study: NCT05065710
Drug: ZL-1211
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1 dose escalation part will enroll about 12-42 patients, Phase 2 dose expansion part will enroll about 15-40 patients in each cohort
Study: NCT06273501
Drug: Magtrace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive superficial and interstitial injection with a 23 G needle with of a total volume of 0.1 - 1 ml Magtrace at four sites in or near the tumor in vulva, the same localization as the injections of Technetium99m and Patent blue for tracing SLNs performed at the surgery. The injection is performed by one of the gynecologic cancer surgeons participating in this study.The time of migration of SPIO to the groin nodes is not known for vulvar cancer. Transportation by dynamic MRI, with selective sequences repeated during a time span of 1- 60 minutes after the injection.
Study: NCT05869812
Drug: CaHMB (Dietary supplement, not Drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigators will focus our effort, for the purposes of this study, on determining if adding an HMB supplement will stimulate positive outcomes and recovery of the quadriceps and hamstrings muscle architecture and function in females with ACL injury requiring surgical repair, more so than a placebo control.
Study: NCT05990985
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone (100mg/d) will be administered by intravenous infusion on day 1-5 in a 3-week treatment cycle.
Study: NCT03763305
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil intravenous continuous infusion for anesthetic induction and maintenance
Study: NCT03763305
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl intravenous injection for anesthetic induction
Study: NCT04823208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05881525
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Study: NCT06291116
Drug: standard care for 24 months.
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard care for 24 months.
Study: NCT06121700
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigator's choice of chemotherapy regimens included SOX, XELOX or FOLFOX. Their usages are as follows:~SOX: S-1 twice a day, days 1-14, the dose of S-1 is accorded to body-surface area (BSA): patients with a BSA of less than 1.25 m2 receive 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 receive 100 mg daily; and those with a BSA of 1.5 m2 or more receive 120 mg daily; and oxaliplatin 130 mg/m2, day 1, every 3 weeks; XELOX: Capecitabine 1000 mg/m2 twice a day, days 1-14 and oxaliplatin 130 mg/m2, day 1, every 3 weeks; FOLFOX: Leucovorin 400 mg/m2, day 1, fluorouracil 400 mg/m2, day 1 and 1200 mg/m2, days 1-2, and oxaliplatin 85 mg/m2, day 1, every 2 weeks.
Study: NCT04855565
Drug: ALY688-SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose subcutaneous injection
Study: NCT06172634
Drug: dentritic cell infusion and immunecheckpoint inhibitor
Normalized name: foslevodopa and decarboxylase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: dentritic cell infusion and immunecheckpoint inhibitor
Study: NCT04969497
Drug: Treatment A: M207 3.8 mg MiniMac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MiniMac coater and packaged in foil cups
Study: NCT04969497
Drug: Treatment B: M207 3.8 mg MACAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MACAP coater and packaged in foil cups
Study: NCT05949021
Drug: Combination of liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of liposomal doxorubicin 30 milligrams per square meter and carboplatin (area under the curve 5), administered every 4 weeks for 4 cycles.
Study: NCT05035277
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 75 mg once daily is the current standard-of-care in TAVI patients without other indications for anticoagulation therapy.
Study: NCT06072573
Drug: Adezunap (AP707)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
Study: NCT06072573
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
Study: NCT05786846
Drug: Iodinated contrast agents
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who use iodinated contrast agents clinically
Study: NCT06633601
Drug: Definity Suspension for Injection
Normalized name: Definity Suspension for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microbubble contrast agents for ultrasound
Study: NCT06301906
Drug: LipoCol Forte Capsule 600mg bid
Normalized name: aspirin 600 MG [Palaprin Forte]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LipoCol Forte Capsule 600mg bid for 12 months
Study: NCT06339697
Drug: different types of laxatives (compounded polyethylene glycol electrolyte dispersions and compounded sodium pico-sulfate)
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel preparation with different types of laxatives (compounded polyethylene glycol electrolytes and compounded sodium picosulfate)
Study: NCT03446807
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules to match Droxidopa 100, 200, and 300mg capsules.
Study: NCT04775615
Drug: DDO-3055 tablets；Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose：DDO-3055 tablets for 7 days or Placebo for 7 days